KPTI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
33.4M
-4.7%
35.1M
+2.9%
34.1M
-22.6%
44.0M
+16.1%
37.9M
Cost of Revenue
1.1M
-19.3%
1.3M
-9.4%
1.5M
-29.8%
2.1M
+101.0%
1.1M
Gross Profit
32.3M
-4.1%
33.7M
+3.5%
32.6M
-22.3%
41.9M
+13.7%
36.9M
Operating Expenses
54.9M
-9.3%
60.5M
+19.9%
50.4M
-11.7%
57.2M
-6.7%
61.3M
R&D
29.0M
-14.3%
33.8M
+22.2%
27.7M
-9.4%
30.5M
-6.8%
32.8M
SG&A
25.9M
-2.9%
26.7M
+17.2%
22.8M
-14.4%
26.6M
-6.6%
28.5M
Operating Income
-22526000
+15.8%
-26760000
-50.0%
-17844000
-17.2%
-15220000
+37.6%
-24387000
EBITDA
-22529000
+15.8%
-26748000
-50.1%
-17825000
-18.1%
-15099000
+37.9%
-24309000
Net Income
-67023000
-199.3%
-22392000
+78.1%
-102198000
-208.5%
-33127000
+11.1%
-37252000
EPS (Basic)
$-2.32
-127.5%
$-1.02
+82.0%
$-5.68
-48.7%
$-3.82
+11.6%
$-4.32
EPS (Diluted)
$-2.32
-87.1%
$-1.24
+78.2%
$-5.68
-48.7%
$-3.82
+11.6%
$-4.32
Shares (Diluted)
28.9M
+17.1%
24.7M
+37.5%
18.0M
+107.4%
8.7M
+0.6%
8.6M
Karyopharm Therapeutics (KPTI) โ€” Financials